Detalhe da pesquisa
1.
Ustekinumab induction and maintenance therapy in refractory Crohn's disease.
N Engl J Med
; 367(16): 1519-28, 2012 Oct 18.
Artigo
em Inglês
| MEDLINE | ID: mdl-23075178
2.
Subcutaneous golimumab maintains clinical response in patients with moderate-to-severe ulcerative colitis.
Gastroenterology
; 146(1): 96-109.e1, 2014 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-23770005
3.
Subcutaneous golimumab induces clinical response and remission in patients with moderate-to-severe ulcerative colitis.
Gastroenterology
; 146(1): 85-95; quiz e14-5, 2014 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-23735746
4.
Comparison of ustekinumab and etanercept for moderate-to-severe psoriasis.
N Engl J Med
; 362(2): 118-28, 2010 Jan 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-20071701
5.
Induction and maintenance therapy with infliximab for children with moderate to severe ulcerative colitis.
Clin Gastroenterol Hepatol
; 10(4): 391-9.e1, 2012 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-22155755
6.
Long-term safety experience of ustekinumab in patients with moderate to severe psoriasis (Part II of II): results from analyses of infections and malignancy from pooled phase II and III clinical trials.
J Am Acad Dermatol
; 66(5): 742-51, 2012 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-21978572
7.
Long-term safety experience of ustekinumab in patients with moderate-to-severe psoriasis (Part I of II): results from analyses of general safety parameters from pooled Phase 2 and 3 clinical trials.
J Am Acad Dermatol
; 66(5): 731-41, 2012 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-21930328
8.
Ustekinumab, a human interleukin 12/23 monoclonal antibody, for psoriatic arthritis: randomised, double-blind, placebo-controlled, crossover trial.
Lancet
; 373(9664): 633-40, 2009 Feb 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-19217154
9.
A human interleukin-12/23 monoclonal antibody for the treatment of psoriasis.
N Engl J Med
; 356(6): 580-92, 2007 Feb 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-17287478
10.
Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1).
Lancet
; 371(9625): 1665-74, 2008 May 17.
Artigo
em Inglês
| MEDLINE | ID: mdl-18486739
11.
Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2).
Lancet
; 371(9625): 1675-84, 2008 May 17.
Artigo
em Inglês
| MEDLINE | ID: mdl-18486740
12.
Baseline nail disease in patients with moderate to severe psoriasis and response to treatment with infliximab during 1 year.
J Am Acad Dermatol
; 58(2): 224-31, 2008 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-18083272
13.
Adverse drug events in infliximab-treated patients compared with the general and psoriasis populations.
J Drugs Dermatol
; 7(12): 1137-46, 2008 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-19137767
14.
A randomized comparison of continuous vs. intermittent infliximab maintenance regimens over 1 year in the treatment of moderate-to-severe plaque psoriasis.
J Am Acad Dermatol
; 56(1): 31.e1-15, 2007 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-17097378
15.
Infliximab treatment improves productivity among patients with moderate-to-severe psoriasis.
Eur J Dermatol
; 17(5): 381-6, 2007.
Artigo
em Inglês
| MEDLINE | ID: mdl-17673380
16.
Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicentre, double-blind trial.
Lancet
; 366(9494): 1367-74, 2005.
Artigo
em Inglês
| MEDLINE | ID: mdl-16226614
17.
Phase 2a, randomized, double-blind, placebo-controlled, multicenter, parallel-group study of a H4 R-antagonist (JNJ-39758979) in Japanese adults with moderate atopic dermatitis.
J Dermatol
; 42(2): 129-39, 2015 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-25491792
18.
Safety, tolerability, and pharmacokinetics of escalating high doses of ivermectin in healthy adult subjects.
J Clin Pharmacol
; 42(10): 1122-33, 2002 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-12362927
19.
Infliximab induction therapy for patients with severe plaque-type psoriasis: a randomized, double-blind, placebo-controlled trial.
J Am Acad Dermatol
; 51(4): 534-42, 2004 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-15389187
20.
Pharmacokinetics of infliximab in children with moderate-to-severe ulcerative colitis: results from a randomized, multicenter, open-label, phase 3 study.
Inflamm Bowel Dis
; 19(13): 2753-62, 2013 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-24193155